Skip to main content
HCPCS J1553 · Level II · Part B drug

J1553: immune globulin (Yimmugo), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J1553

Billing unit
100 MG
Inj yimmugo 100 mg
ASP payment limit
$21.664
October 2026; -10.3% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0923
NCCI exposure
no PTP pairs
Coverage articles
3
14 states

TL;DR

HCPCS J1553 is the Level II code for Injection, immune globulin (yimmugo), 100 mg, billed per 100 MG. The Medicare Part B ASP payment limit for October 2026 is $21.664 per billing unit, down 10.3% from July 2026. Under OPPS it carries status indicator K in APC 0923. J1553 is billed in units of 100 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names immune globulin: J1551 (Cutaquig); J1555 (Cuvitru from Takeda Pharmaceuticals America, Inc); J1558 (Xembify from Grifols USA, LLC); J1559 (Hizentra from CSL Behring L.L.C); J1577 (Qivigy); J1552 (Alyglo from GC Biopharma USA, Inc.; billed per 500 mg). The ASP crosswalk maps 3 NDCs to it, sold as Yimmugo by Kedrion Biopharma Inc. 3 Medicare coverage articles list the code across 11 states plus DC and 2 territories, including A56786.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J1553 at $21.664 per 100 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $24.145 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J1553
QuarterPayment limitPerCoinsurance
October 2026$21.664100 MG20%
July 2026$24.145100 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 3 NDCs from 1 labeler to J1553. Report the NDC in the claim's drug segment and bill the number of J1553 units that equals the quantity administered divided by 100 MG; the last column gives units per full package.

NDCs that crosswalk to J1553
NDCDrug nameLabelerPackage sizeBilling units / package
83372-0605-01YimmugoKedrion Biopharma Inc50 × 150
83372-0605-11YimmugoKedrion Biopharma Inc100 × 1100
83372-0605-21YimmugoKedrion Biopharma Inc200 × 1200

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for J1553 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for J1553 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J1553 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J1553 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J1553 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

3 current Medicare Administrative Contractor articles list J1553 in their HCPCS tables, covering 14 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J1553
ArticleTitleContractor(s)StatesRelated LCD
A56786Billing and Coding: Immune GlobulinNovitas Solutions, Inc.DC DE MD NJ PAL35093
A57187Billing and Coding: Immune Globulin Intravenous (IVIg)Noridian Healthcare Solutions, LLCAZ MT ND SD UT WYL34314
A57778Billing and Coding: Immune GlobulinFirst Coast Service Options, Inc.FL PR VIL34007

Diagnoses Medicare contractors cover for J1553

3 billing and coding articles attach a covered diagnosis list to J1553: 150 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J1553
ICD-10-CMDescription (FY2027)Articles covering
C90.00Multiple myeloma not having achieved remission3 of 3
C90.02Multiple myeloma in relapse3 of 3
C91.10Chronic lymphocytic leukemia of B-cell type not having achieved remission3 of 3
C91.12Chronic lymphocytic leukemia of B-cell type in relapse3 of 3
D59.0Drug-induced autoimmune hemolytic anemia3 of 3
D59.11Warm autoimmune hemolytic anemia3 of 3
D59.12Cold autoimmune hemolytic anemia3 of 3
D59.13Mixed type autoimmune hemolytic anemia3 of 3
D59.19Other autoimmune hemolytic anemia3 of 3
D69.3Immune thrombocytopenic purpura3 of 3
D80.0Hereditary hypogammaglobulinemia3 of 3
D80.1Nonfamilial hypogammaglobulinemia3 of 3
D80.2Selective deficiency of immunoglobulin A [IgA]3 of 3
D80.3Selective deficiency of immunoglobulin G [IgG] subclasses3 of 3
D80.4Selective deficiency of immunoglobulin M [IgM]3 of 3
135 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J1553 are counted here: a group whose instructions name J1553, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J1553, by article
ArticleContractorGroups that applyCovered codes for J1553Full list
A56786Novitas Solutions, Inc.group 1 applies to J1553108On LCD L35093
A57187Noridian Healthcare Solutions, LLCone list for every code in the article103On LCD L34314
A57778First Coast Service Options, Inc.group 1 applies to J1553108On LCD L34007

Local coverage policies that list J1553

4 active Local Coverage Determinations list J1553 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J1553 carries status indicator K and is assigned to APC 0923, with a published national unadjusted payment of $21.664. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J1553 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $21.66 per 100 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J1553 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J1553

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J1553

What does HCPCS code J1553 describe?

J1553 is defined by CMS as "Injection, immune globulin (yimmugo), 100 mg". Each billing unit represents 100 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J1553 a CPT code?

No. J1553 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as immune globulin (Yimmugo); CPT codes are five-character codes maintained by the AMA. On a Part B claim J1553 reports the drug itself in 100 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J1553 in October 2026?

The ASP-based payment limit is $21.664 per 100 MG, with 20% beneficiary coinsurance. The July 2026 limit was $24.145. Commercial payers use their own fee schedules.

Which NDCs map to J1553?

The October 2026 ASP crosswalk lists 3 NDCs from 1 labeler: Yimmugo (Kedrion Biopharma Inc). For example NDC 83372-0605-01 (package size 50) equals 50 billing units of J1553.

Does J1553 have NCCI bundling edits?

No active practitioner PTP pairs list J1553 as a column-1 or column-2 code in the v323r0 release.

J1553 vs J1551: what is the difference?

Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1551 apart: Cutaquig. J1553 is billed per 100 mg, limit $21.664; J1551 is billed per 100 mg, limit $14.172, MUE 1600. Report the code whose descriptor matches the product and setting in the record.

J1553 vs J1555: what is the difference?

Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1555 apart: Cuvitru from Takeda Pharmaceuticals America, Inc. J1553 is billed per 100 mg, limit $21.664; J1555 is billed per 100 mg, limit $17.994, MUE 480. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J1553?

3 current Billing and Coding Articles in the Medicare Coverage Database list J1553, covering 11 states plus DC and 2 territories: A56786 (Billing and Coding: Immune Globulin); A57187 (Billing and Coding: Immune Globulin Intravenous (IVIg)); A57778 (Billing and Coding: Immune Globulin).

What diagnosis codes support J1553?

3 Medicare billing and coding articles list 150 covered ICD-10-CM codes for J1553 between them, for example C90.00 (Multiple myeloma not having achieved remission); C90.02 (Multiple myeloma in relapse); C91.10 (Chronic lymphocytic leukemia of B-cell type not having achieved remission); C91.12 (Chronic lymphocytic leukemia of B-cell type in relapse); D59.0 (Drug-induced autoimmune hemolytic anemia). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.